CSI Medical Research Pte Ltd   Report issue

For profit Phase 2
Founded: Singapore Singapore (2018)

Organization Overview

First Clinical Trial
2019
NCT03932513
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

CSI Medical Research Pte Ltd

Active Ingredients

Drugs in Phase 2 Trials (1)

inarigivir (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis B (Phase 2)

Hepatitis B, Chronic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1